
Can Wang Xiaochuan Turn a Medical-AI Bet into an IPO by 2027?
Wang Xiaochuan has repositioned Baichuan Intelligence from a broad generalist-AI play to an all-in bet on medical AI, promising patient-facing decision support and an IPO push in 2027. The company faces steep hurdles: fierce competition from better-resourced incumbents, the high cost and time of clinical validation, regulatory and privacy burdens, and uncertain consumer willingness to pay.


















